Nomination committee’s proposal to composition of the Board
The Nomination Committee of Meda AB proposes the election of Karen Sörensen as new board member. The committee also proposes the re-election of Peter Claesson, Peter von Ehrenheim, Marianne Hamilton, Tuve Johannesson, Anders Lönner and Lars Westerberg as board members. Bert-Åke Eriksson is proposed to be re-appointed as board chairman.
Karen Sörensen is currently CEO of Philips Nordic and responsible for Philips Healthcare Nordic. She was previously Vice President of Sanofi-Aventis with responsibility for western Europe. Sörensen has experience from several global pharmaceutical-, biotechnology- and medical technology companies. She holds a Master of Science and an MBA from INSEAD.
The nomination committee for the AGM 2013 consists of Evert Carlsson (Swedbank Robur Funds), Bengt Belfrage (Nordeas Funds), Anders Oscarsson (AMF Funds), Bert-Åke Eriksson (Meda’s chairman of the board) and Karl-Magnus Sjölin (Stena Sessan).
The nomination committee's other proposals concerning the chairman of the meeting, remuneration and the method used to appoint the nomination committee will be disclosed on the website and in the notice of the Annual General Meeting.
The Annual General Meeting of Meda AB will be held on May 7, 2013 at 17.00 CET at Meda AB, Pipers väg 2A, Solna.
For further inquiries, please contact:
Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878
Karl-Magnus Sjölin, Chairman of the Nomination Committee ph: +46 31-774 35 35
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
Forward-looking statements
This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe” or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.
